^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
966 Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study
Published date:
11/02/2023
Excerpt:
In a dose-escalation study, we evaluated the safety, tolerability, and preliminary efficacy of blina with nivolumab (nivo) +/- ipilimumab (ipi) using a 3+3 design. Pts ³16 years-old with R/R CD19+ B-ALL or mixed phenotype acute leukemia (MPAL) were eligible....Combination therapy with blina and ICIs in R/R ALL is safe, feasible, and associated with a high MRD-negative response rate. Long-term survival was promising in comparison to prior results with blina monotherapy, especially following consolidation with alloBMT.
